Advancing novel treatments for dry eye and ocular surgery


Kala Pharmaceuticals (NASDAQ: KALA) is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which we have submitted a NDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, which is currently in Phase 3 clinical development.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

January 5, 2018
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease

January 5, 2018
Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration

November 13, 2017
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner